Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older

Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi, Andreas Wollenberg, Michael J. Cork, Danielle Marcoux, Rui Huang, Zhen Chen, Ana B. Rossi, Brad Shumel, Debra Sierka, Ashish Bansal

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: In phase III trials in adolescents and children with atopic dermatitis (AD), dupilumab significantly decreased global disease severity. However, the effects of dupilumab on the extent and signs of AD across different anatomical regions were not reported. Here we characterize the efficacy of dupilumab in improving the extent and signs of AD across four different anatomical regions in children and adolescents. Methods: A post hoc subset analysis was performed using data from two randomized, double-blind, placebo-controlled, international multicenter, phase III trials of dupilumab therapy in adolescents aged ≥ 12 to < 18 years with moderate-to-severe AD and children aged ≥ 6 to < 12 years with severe AD. Endpoints included mean percentage change in Eczema Area and Severity Index (EASI) signs (erythema, edema/papulation, excoriation, lichenification) and extent of AD (measured by percentage of body surface area [% BSA] involvement) from baseline to week 16 across four anatomical regions (head and neck, trunk, upper extremities, lower extremities). Results: Dupilumab improved both the extent and severity of AD signs across the four anatomical regions. Improvements were shown to be similar across the four anatomical regions for % BSA involvement and for reduction in EASI signs. Improvements in all signs were seen early, within the first 4 weeks of treatment, and were sustained through week 16, across all regions. Conclusions: In pediatric patients 6 years of age and older, treatment with dupilumab resulted in rapid and consistent improvement in the extent and signs of AD across all anatomical regions. ClinicalTrials.gov Identifiers: LIBERTY AD ADOL (NCT03054428) and LIBERTY AD PEDS (NCT03345914). [MediaObject not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)1643-1656
Number of pages14
JournalDermatology and Therapy
Volume11
Issue number5
DOIs
StatePublished - Oct 2021

Keywords

  • Anatomical regions
  • Atopic eczema
  • Contact dermatitis
  • Cytokines
  • Dupilumab
  • Facial erythema
  • Immunology
  • Patients
  • Pediatric dermatology
  • Signs

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older'. Together they form a unique fingerprint.

Cite this